Results

Kura Oncology Inc.

05/06/2021 | Press release | Distributed by Public on 05/07/2021 01:34

KOMET-001 trial amended to include Phase 1b expansion cohorts enriched with NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients